PREMIER PRODUCT

COBALIS COMPANY NEWS

The following are recent important news releases by and about Cobalis, and its premier allergy prevention product PreHistin™:

Note: You will need Adobe Acrobat Reader installed to view the document. Click here to download Adobe Acrobat Reader.

 

2007 | 2006 | 2005 | 2004 | 
Filing Date   Description Downloads
12/14/04   Dr. Lawrence A. May, Former EVP and Chairman of Herbalife Medical Advisory Board, Joins Cobalis Board of Directors 1 Acrobat pdf file
12/09/04   Cobalis Successfully Completes Enrollment of 713 Patients and Starts 6-Week Clinical Study as a Part of Ongoing Phase III Trial for PreHistin™ 1 1 Acrobat pdf file
11/04/04   Cobalis Corp. to Start 6-Week Clinical Trial Study With 624 Patients on November 29, 2004 as Part of Ongoing Phase III Trials For PreHistin™ 1 1 Acrobat pdf file
11/03/04   Cobalis Corp. Receives IRB Approval To Process With Phase III Clinical Trials For PreHistin™ 1 1 Acrobat pdf file
11/02/04   Cobalis Corp. Announces Significant Debt-to-Equity Conversion 1 1 Acrobat pdf file
10/13/04   NASDAQ Notifies Cobalis That It Will Remove "V" From Its Stock Symbol – An Update on Mandatory Share Certificate Exchange 1 1 Acrobat pdf file
08/27/04   Cobalis Changes Its Trading Symbol From “CBSC” TO “CLSC” - Update On Mandatory Share Certificate Exchange     Acrobat pdf file
08/23/04   Cobalis Corp. To Require Mandatory Share Certificate Exchange     Acrobat pdf file
>>
   Link To Letter Of Transmittal 1 Acrobat pdf file
07/26/04   Cobalis to Commence Phase II Clinical Trials for Use of PreHistin™ To Prevent Atopic (Common) Migraine     Acrobat pdf file
07/20/04   Cobalis Corp gains Superior Court Approval to Cancel 3,000,000 Share Certificate Held by IBCG as the Defaulting Party to Loan Agreement     Acrobat pdf file
07/15/04   BioGentech Changes Its Name to Cobalis     Acrobat pdf file
07/07/04   BioGentech Receives FDA Approval for Phase III Clinical Trials Study Design For PreHistin™     Acrobat pdf file
04/02/04   BioGentech Corp. Awarded Australian Patent Covering the Use of Cyanocobalamin (Vitamin B12) for the Treatment of Seasonal Allergies     Acrobat pdf file
04/01/04   BioGentech Finalizes Outsourcing Partnerships for PreHistin™ Phase III Clinical Trials     Acrobat pdf file
03/26/04   BioGentech Receives FDA Approval to Begin Phase III Clinical Trials: PreHistin™ to Prevent the Symptoms of Seasonal Allergic Rhinitis (Hay Fever)     Acrobat pdf file
2007 | 2006 | 2005 | 2004 | 

 

Read COBALIS CORPORATE CONTACT INFORMATION
 

IMPORTANT NOTICE:
The FDA has not completed evaluation of PreHistin™, and the information and statements contained in this web site are intended for informational purposes only. They are not meant to imply a cure or approved treatment for any disease or condition. You are encouraged to consult your physician for any healthcare questions or concerns you may have about your allergies.

Copyright 2005-2006 Cobalis Corp.
Site Map

Design by www.de3ign.com
Created by BARDS